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Remission was once an unusual phenomenon in rheuma-
tology, despite references to disease-modifying antirheu-
matic drugs (DMARDs) as ‘remission-inducing’. In the 
previous issue of Arthritis Research & Th  erapy, the study 
by Saber and colleagues [1] provides further evidence of 
remission as a reachable goal in a usual rheumatology 
clinic. Th   e authors report a DAS28 (disease activity score 
using 28 joint counts) remission rate of 58% in psoriatic 
arthritis patients who were treated with anti-tumor 
necrosis factor therapy for 12 months.
Remission started its eventful and ambitious journey in 
the 1990s in patients with rheumatoid arthritis (RA). It 
was deﬁ   ned as the treatment goal and the primary 
outcome measure in the Finnish Rheumatoid Arthritis 
Combination Th  erapy (FIN-RACo) trial [2] in 1993, 
6 years before the ﬁ  rst biologic agent became available. 
Nonetheless, the results of the FIN-RACo trial were 
amazing: 42% of those who received a combination of 
conventional DMARDs were in remission 2 years after 
baseline, entirely without signs and symptoms of RA, and 
68% met the DAS28 remission criteria [3]. Th  e  ﬁ  ndings 
indicated that a strategy of ‘tight control’ appeared to be 
more important than a speciﬁ  c agent in the control of RA.
Subsequent studies conﬁ   rmed the importance of a 
‘tight control’ strategy directed to ‘treat to target’ accord-
ing to a quantitative goal. Th   e TICORA (Tight Control of 
Rheumatoid Arthritis) trial reported a remission rate of 
65% using conventional DMARDs. In the CIMESTRA 
(Cyclosporine, Methotrexate, Steroid in Rheumatoid 
Arthritis) trial, remission rates were 59% and 54% for 
DAS28 remission and 41% and 35% for American College 
of Rheumatology (ACR) remission at 2 years in the 
combination and monotherapy arms, respectively [4]. In 
the BeSt (Behandelstrategieën voor Reumatoide Artritis) 
study of treatment strategies for RA, 38% to 46% of 
patients in the four arms were in remission at the end of 
intervention [5].
At this time, remission rates for RA in usual clinical 
care are higher than in the past [6], though primarily in 
North America and Western Europe [7]. Similarly, the 
clinical status of RA patients who are treated actively in 
rheumatology clinics has improved substantially com-
pared with previous decades [8,9].
A single ‘gold standard’ measure is not available for 
disease activity in RA or other inﬂ  ammatory  joint 
diseases, and simple criteria for deﬁ  ning remission must 
include multiple measures. Preliminary remission criteria 
for RA were proposed by a committee of the American 
Rheumatism Association (now the ACR) in 1981 [10]. 
According to these criteria, remission is present if ﬁ  ve of 
the following conditions are met: absence of morning 
stiﬀ  ness, fatigue, joint pain, tenderness, and swelling and 
presence of normal erythrocyte sedimentation rate. 
However, these criteria are too stringent and are not 
based on real-world data; for example, mild pain is 
common in the population over age 50, and 85% would 
not meet ACR remission criteria [11]. Th  e use of less 
stringent deﬁ   nitions of remission such as remission 
according to DAS28 has opened rheumatology for the 
concept of remission in a large number of patients [12], 
as shown by Saber and colleagues [1] in patients with 
psoriatic arthritis.
Psoriatic arthritis is a multifaceted disease. Global 
remission should involve the absence of peripheral 
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Fifty-eight percent, a high percentage for DAS28 remission 
[1], may be an overestimate compared with a real 
remission rate. However, no consensus about remission in 
psoriatic arthritis exists, and various criteria have been 
used to deﬁ  ne remission [13], just as various criteria were 
used to deﬁ   ne remission in RA [7]. In both diseases, 
remission has been deﬁ  ned as the treatment target [13,14].
Routine quantitative monitoring of rheumatology 
patients has been advocated for almost 3 decades. 
However, it appears that only the availa  bility of biologic 
agents can direct rheumatologists’ interest into routine 
monitoring of patients’ pain, func  tional status, and 
disease activity. Th   e patients of Saber and colleagues [1] 
were assessed every 3 months for disease activity and 
patient-reported outcomes. Remission is an achievable 
goal in rheumatology at this time, and routine monitoring 
of patients may make its way to rheumatology after a 
three-decade-long journey.
Finally, there is nothing new under the sun: Th  e  Health 
Assessment Questionnaire (HAQ) is the best predictor of 
the future [15] (in this case, remission). Th  is  observation 
by Saber and colleagues [1] conﬁ  rms what many reports 
have been showing for the past 20 years: HAQ is the best 
predictor of mortality, work disability, functional status, 
and even joint replacements and health care costs.
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